Molecule ONE
Dover, US · Founded 2020 · Delaware corporation · 37 employees on LinkedIn · 5 known investors
Find your way into Molecule ONE
77 people in our graph share verified history with the Molecule ONE team — schools, employers, funds. One of them is your warm intro.
Molecule.one applies machine learning to chemical synthesis, predicting synthetic routes and supporting chemistry research with an in-house synthetic and analytical laboratory. It serves pharmaceutical and life-science research through its computational and experimental chemistry platform.
Also known as Molecule One sp. z o.o. · molecule.one · Molecule.one
Founders & leadership
Molecule ONE was founded in 2020 by Pawel Wlodarczyk-Pruszynski, Piotr Byrski, Stanisław Jastrzębski, and Paweł Włodarczyk-Pruszyński.
Board
Investors · 5
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$4.6M disclosed across 1 round · 2021
▶$4.6MraisedMay 2021 · 12 investors · Other TechnologyRule 506(b)
- Pawel Wlodarczyk-PruszynskiExecutive Officer, Director
- Dominik AndrzejczukDirector
- Piotr ByrskiExecutive Officer, Director
- Offering amount
- $4.6M
- Amount sold
- $4.6M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 04, 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Molecule.one develops artificial intelligence for chemical synthesis and drug discovery, centred on a platform it calls Maria. The platform combines three elements: Maria AI, an agentic framework built around chemistry models used to plan and solve chemical problems; the Maria Lab, a microliter-scale high-throughput experimentation (HTE) facility operated according to the AI system's instructions; and Maria Data, a proprietary experimental dataset generated in that lab. The company positions the combination as supporting near-autonomous research workflows for drug discovery and manufacturing.
The business also provides chemical synthesis services for drug discovery, including direct-to-biology plates of compounds drawn from a proprietary compound space referred to as SpaceM1. Using generative models together with a dataset described as exceeding 100,000 reactions from its high-throughput experimentation lab (established in 2021), it offers customers access to a large library of de novo drug-like molecules with reported synthesis turnaround of roughly two to six weeks.
The company publishes peer-reviewed and workshop research on machine learning for chemistry, including work on modeling chemical reactions as sequences of graph edits (JCIM, 2021), a relative molecule self-attention transformer (Journal of Cheminformatics, 2024), retrosynthesis methods that mitigate hallucinations through reaction plausibility filtering and retrieval-augmented scoring, and scaling of high-throughput experimentation for reaction-outcome prediction (both NeurIPS AI4Science workshop, 2025), alongside case studies on hit discovery, hit-to-lead campaigns and non-pharmaceutical industrial applications.
Business model
Business-to-business services sold to pharmaceutical and biotech organisations, delivered through project-based contracts and success-fee arrangements around customized synthesis work powered by the company's platform, together with strategic collaborations with industrial and information-services partners.
Revenue is generated primarily through B2B partnerships with pharmaceutical and biotech firms, structured as project-based contracts and success-fee agreements for synthesis services.
Traction
Reported revenue of USD 348,325 and EBITDA of USD 142,116 for 2023, following revenue of USD 43,277 in 2019 and USD 555,282 in 2020. The company established a high-throughput experimentation lab in 2021, accumulated a dataset of more than 100,000 reactions, and has announced collaborations with CAS (2023), Standard Industries (2025), W.R. Grace (2025) and OpenAI.
Latest developments
In August 2023 the company announced a strategic collaboration with CAS to accelerate drug discovery. In June 2025 Standard Industries named it winner of a $1 million AI challenge. In December 2025 it announced work with W.R. Grace on peptide building block synthesis using AI and automation. In June 2026 it reported, with OpenAI, an experiment in which GPT-5.4 and Maria AI selected a research area, generated and rated proposals, and ran experiments in the Maria Lab to improve a challenging medicinal-chemistry reaction.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned as an AI-plus-automated-lab provider for synthesis in drug discovery, with commercial partnerships including CAS and W.R. Grace and recognition as winner of a $1 million AI challenge run by Standard Industries.
Technology
Maria, an agentic AI framework combining frontier chemistry models, is paired with a purpose-built microliter-scale high-throughput experimentation laboratory and a dataset generated at the AI's direction. Underlying research covers graph-edit models of chemical reactions, self-attention transformers for molecules, retrosynthesis with reaction plausibility filtering and retrieval-augmented scoring, and machine-learning models for reaction-outcome prediction. The SpaceM1 platform uses generative models and a library of more than 100,000 HTE reactions to give access to over one trillion de novo drug-like molecules.
Go-to-market
Pharmaceutical companies and research institutions, plus industrial customers outside pharma; clients are located in North America, Europe and Asia.
Geography
Operations based in Warsaw, Poland, serving clients in North America, Europe and Asia, with stated plans to open offices in the United States and Western Europe by 2025.
History
The company operates as Molecule One sp. z o.o. out of Warsaw, Poland, with an establishment date recorded as 2016 by one data provider. It raised a seed round in June 2021 and built a high-throughput experimentation laboratory that same year, later expanding into agentic AI systems and industrial partnerships.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 4
by search overlap
Companies competing with Molecule ONE for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 4
launches, deals, and filingsMolecule.one and OpenAI report that GPT-5.4 and Maria AI selected a research area, generated and rated proposals, and ran experiments in the Maria Lab on an open-ended organic chemistry problem.
$1M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 4
primary sources listed
- Molecule ONEmolecule.one · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Molecule ONE do?
- Molecule.one builds AI systems and an automated microliter-scale lab for chemical synthesis and drug discovery.
- Who founded Molecule ONE?
- Molecule ONE was founded by Pawel Wlodarczyk-Pruszynski, Piotr Byrski, Stanisław Jastrzębski, Paweł Włodarczyk-Pruszyński in 2020.
- Who are Molecule ONE's investors?
- Molecule ONE's investors include Expeditions, Ff Venture Capital, Sunfish Partners.
- How much funding has Molecule ONE raised?
- Molecule ONE has disclosed $4.6M raised across 1 round.
- Where is Molecule ONE headquartered?
- Molecule ONE is headquartered in Dover, US.